Overview

Study of PF614 Compared to OxyContin® in Healthy Volunteers

Status:
Completed
Trial end date:
2018-01-10
Target enrollment:
Participant gender:
Summary
PF614 is an oxycodone prodrug that is designed for extended-release of oxycodone comparable to OxyContin. This Single Ascending Dose (SAD) study is designed to assess the safety and pharmacokinetics (PK) of PF614 in comparison to standard doses of OxyContin.
Phase:
Phase 1
Details
Lead Sponsor:
Ensysce Biosciences
Collaborator:
PRA Health Sciences
Treatments:
Naltrexone
Oxycodone